[HTML][HTML] Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S De Biasi, M Mattioli, M Meschiari… - Frontiers in …, 2023 - frontiersin.org
Introduction A growing number of evidences suggest that the combination of
hyperinflammation, dysregulated T and B cell response and cytokine storm play a major role …
hyperinflammation, dysregulated T and B cell response and cytokine storm play a major role …
[HTML][HTML] Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S De Biasi, M Mattioli, M Meschiari… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
Methods In the present study, we investigated the impact of two doses of tocilizumab in
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S DE BIASI, M Mattioli, M Meschiari… - FRONTIERS IN …, 2023 - iris.unimore.it
Introduction: A growing number of evidences suggest that the combination of
hyperinflammation, dysregulated T and B cell response and cytokine storm play a major role …
hyperinflammation, dysregulated T and B cell response and cytokine storm play a major role …
[PDF][PDF] Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S De Biasi, M Mattioli, M Meschiari, DL Tartaro… - 2023 - scienceopen.com
Methods: In the present study, we investigated the impact of two doses of tocilizumab in
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S De Biasi, M Mattioli, M Meschiari, L Tartaro… - Frontiers in …, 2023 - europepmc.org
Methods In the present study, we investigated the impact of two doses of tocilizumab in
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S De Biasi, M Mattioli, M Meschiari… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
Introduction A growing number of evidences suggest that the combination of
hyperinflammation, dysregulated T and B cell response and cytokine storm play a major role …
hyperinflammation, dysregulated T and B cell response and cytokine storm play a major role …
Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab.
S De Biasi, M Mattioli, M Meschiari, L Tartaro… - Frontiers in …, 2023 - europepmc.org
A growing number of evidences suggest that the combination of hyperinflammation,
dysregulated T and B cell response and cytokine storm play a major role in the …
dysregulated T and B cell response and cytokine storm play a major role in the …
[PDF][PDF] Prognostic immune markers identifying patients with severe COVID-19 who respond to tocilizumab
S De Biasi, M Mattioli, M Meschiari, DL Tartaro… - 2023 - iris.unimore.it
Methods: In the present study, we investigated the impact of two doses of tocilizumab in
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …
patients with severe COVID-19 who responded or not to the treatment by analyzing a panel …